The BCIRG 006 trial is relevant for all Her2 positive disease, both ER positive and ER negative. Depending on the risk profile of the patient (T2 disease and beyond), I give T...

Worth noting that ER/PR status would impact this decision -- significant residual disease in a HR+ HER2+ patient would potentially argue for moving on to endocrine therapy rat...

I would treat this patient with chemotherapy and anti Her-2 therapy. Her-2 positive disease has a higher risk of distant recurrence and as long as the primary tumor is >0.5...

I tend to reserve neo-adjuvant chemotherapy for patients with cT2 or higher if there is no clinical evidence of positive lymph nodes. The results of APT trial that enrolled pa...

This becomes a philosophical question...arguments can be made for either approach. My approach is to offer everything within reason, as opposed to omitting parts of treatment ...

Dr. @Anjali Budhathoki, we do have this Q&A, as well as another Q&A that discusses N1mic HER2+ patients that you may find of interest.

So far, insurance companies in my area are not approving TDM1 in this setting because there is no overall survival advantage at this point.

I agree that TCHP is equivalent to AC-TH with less cardiac toxicity. 

I would switch to weekly paclitaxel and carboplatin with trastuzumab only, but might retry pertuzumab if the patient gets through 6 weeks without recurrent diarrhea. This is a...